Compare Organon & Co. Common Stock (OGN) vs Vanguard Value Index Fund ETF (VTV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Vanguard Value Index Fund ETF — how do they compare? Organon & Co. Common Stock trades at $13.73 (market cap $3.61B), while Vanguard Value Index Fund ETF trades at $221.56 (market cap $262.40B). The key difference: Vanguard Value Index Fund ETF is far larger — about 72.7× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Vanguard Value Index Fund ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Vanguard Value Index Fund ETF for 143 Days on average.
| OGN | VTV | |
|---|---|---|
Market Cap | $3.61B | $262.40B |
Volume | 1,808,049 | 2,800,630 |
Sector | Health | — |
52-Week High | $13.81 | $227.51 |
52-Week Low | $5.70 | $182.89 |
Typical Hold Time | 0 Days | 143 Days |
Enterprise Value | $11.03B | — |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
VTV trades at $220.67, down 0.34% on the day, with a bullish technical signal supported by moving averages but mixed oscillators. The ETF shows strong institutional interest with recent acquisitions by QRG Capital Management and Blue Edge Capital. Recent news highlights VTV's 2.3% dividend yield and value-focused strategy outperforming growth counterparts in 2026, with value stocks gaining traction amid market rotation away from tech concentration.
VTV presents a compelling value proposition with low 0.03% fees and income appeal, though long-term performance trails the S&P 500. Key risks include sustained growth stock dominance and interest rate sensitivity. The ETF's diversification across value stocks positions it well for investors seeking stability amid market uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Vanguard Value Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the CRSP US Large Cap Value Index, a broadly diversified index predominantly made up of value stocks of large US companies. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VTV →
